Dr. Matthew Harris, Harvard Medical School presents a seminar entitled "Hidden just below the surface: latent morphogenetic potential and innovation"
Dr. Debashish Bhattacharya, Rutgers University presents a seminar entitled "Learning the basics of coral biology to aid reef conservation"
https://dbm.rutgers.edu/personnel/faculty/debashish-bhattacharya
Dr. Adam Session, Binghampton University presents a seminar entitled "Establishing the Xenopus polyploidy as a model for vertebrate genome evolution"
https://www.binghamton.edu/biology/people/profile.html?id=asession
Dr. Michael Gebhardt, University of Iowa presents a seminar entitled "Exploring the essentiality of post-transcriptional regulators in Acinetobacter baumannii"
https://microbiology.medicine.uiowa.edu/profile/michael-gebhardt
Dr. Sunny Shin, University of Pennsylvania presents a seminar entitled "Innate immune defense against bacterial infection"
Dr. Morgan Gilman, Boston University presents a seminar entitled "Molecular-Level Understanding of Human Pathogens to Inform Therapeutic Development"
https://profiles.bu.edu/Morgan.Gilman
Dr. David Mark Welch, University of Chicago, Marine Biological Lab presents a seminar entitled "Stress Resistance and the Evolution of Genetic Novelty in Bdelloid Rotifers"
https://researchdevelopment.uchicago.edu/project/david-mark- welch/
Dr. Tovah Day, Northeastern University presents a seminar entitled "Unraveling G Quadruplex DNA: Cellular Mechanisms Regulating Its Impact on Signaling and Genomic Instability."
https://cos.northeastern.edu/people/tovah-day/
Dr. Katie Lotterhos, Northeastern University presents a seminar entitled “Inversions as concentrators of a polygenic architecture: the evolution of migratory body shape in a marine fish.”
Joseph Inigo is a lecturer in the MS Biotechnology program at Northeastern University. He received his PhD in Pharmacology and Cancer Therapeutics from the University at Buffalo, Roswell Park Comprehensive Cancer Center. His research studies included identification of mitochondrial targets for cancer therapy, small molecule drug discovery, and development of genetically engineered mouse models of cancer.
Joseph has experience as a scientist in biotech, developing non-viral gene therapy for hematologic diseases. He also has experience in Business Development, conducting competitive intelligence research to guide pipeline strategy.
A Northeastern University researcher has identified a way to target two of the deadliest cancer types, melanoma and triple negative breast cancer, with chemotherapy drugs but without the harms associated with chemotherapy.
Both cancers are typically resistant to chemotherapy, says Fleury Augustin Nsole Biteghe, a lecturer in biotechnology, chemistry and chemical biology. But by attaching a light-sensitive drug to a protein called MTf — which appears abundantly in both cancers — and bathing the drug-infused protein in near-infrared light, cancer cells die.
Using antibodies to target cancer proteins is typically performed by using multiple drugs at once, Nsole Biteghe says. But this approach stimulates the immune system so much that it can end up attacking healthy body tissues, he says.
“The antibody is like a key and we know what the lock is,” he says.
Read more at Northeastern Global News.
Photo by Matthew Modoono/Northeastern University